PrecisionPhage participates in WeNSC

In today’s presentation, CEO Matti Jalasvuori discussed the journey of PrecisionPhage from research to a biotech company. He explained how the decade of study of bacteriophages, viruses that target and kill bacteria, led to the foundation of PrecisionPhage. The company focuses on using phages to combat antibiotic-resistant infections.